RxDoctor Payments Data

Gwen Williams, MD

Rheumatology · Birmingham, ALNPI 1912975590

Payments from drug & device makers

$486in general payments, 2019–2025

Across 21 payments — averaging $23.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$154
  • Pacira Pharmaceuticals Incorporated$55
  • Sanofi-aventis U.S. LLC$43
  • Molnlycke Health Care US, LLC$36
  • Pacira Therapeutics, Inc.$35
  • Endo Pharmaceuticals Inc.$32
  • plus $132 from 7 others

What the payments were for

  • Food & beverage$486100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$486 in reported general payments places this provider in the 15th percentile of 90 rheumatology providers in Alabama.

See all rheumatology providers in Alabama

Medicare billing

Part B allowed, 2024
$53,171
Medicare patients
177
Services billed
3,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab29$390,042
Humira PenAdalimumab33$223,858
HumiraAdalimumab18$121,881
EnbrelEtanercept13$91,842
OtezlaApremilast12$56,547
Hydroxychloroquine Sulfate393$31,141
MethotrexateMethotrexate Sodium415$15,808
Prednisone587$5,635
Gabapentin383$3,849
Duloxetine Hcl104$3,699
Leflunomide88$3,260
Tizanidine Hcl112$3,039
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen187$2,425
Pregabalin26$2,048
Colchicine23$1,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla$154$148,39025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 90 rheumatology providers in Alabama.

Other rheumatology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →